Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced a limited-time $0 copay offering for commercially eligible patients effective now through April 30, 2020 as a response to the COVID-19 pandemic.“In this time of uncertainty, people with diabetes need a glucagon product they can easily administer if their blood sugar goes severely low. Unfortunately, most people with diabetes on insulin either don’t have glucagon at home or have an antiquated glucagon kit that studies have shown very few people can correctly administer especially under duress. To quickly change this paradigm and relieve the stress of financial barriers, we are offering a $0 copay card through the end of April. Simply put, anyone with commercial insurance that gets a prescription for Gvoke PFS will pay $0 out
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions [Yahoo! Finance]Yahoo! Finance
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Xeris Biopharma: Checking-In On One Of My 'Top Ideas' [Seeking Alpha]Seeking Alpha
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.MarketBeat
XERS
Earnings
- 3/6/24 - Miss
XERS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- XERS's page on the SEC website